On August 12, 2013, the FDA announced the approval of Tivicay (dolutegravir) for the treatment of human immunodeficiency virus (HIV). Tivicay is a member of a class of medications, used to manage HIV, known as integrase inhibitors. Integrase inhibitors work by preventing HIV from inserting its genetic material into the DNA of a host cell. By preventing this activity, Tivicay can halt additional spread of HIV within a particular infected patient.
Tivicay has been approved for the treatment of HIV in a wide variety of patient populations, including adult patients infected with HIV who have never received treatment for HIV as well as those who have previously received therapy for HIV, including those who have been treated with other integrase inhibitors.
Tivicay has also been approved for use in children over the age of 12 and weighing at least 40 kg (88 lb) regardless of whether or not they have received previous HIV therapy, but have not previously received an integrase inhibitor.
It is important to note that of the medications approved for the treatment of HIV, none of them (including Tivicay) are fully curative. Approved HIV medications work by reducing the amount of virus in the body. Thus, Tivicay will provide another option for healthcare professional seeking to choose the right medication regimen for their patients infected with HIV. According to Dr. John Pottage, Chief Medical Officer, ViiV Healthcare, “HIV treatment should not be a ‘one-size fits all’ paradigm.”
Diplomat will be able to distribute Tivicay once it becomes available. You can learn more about our patient services for HIV/AIDS here. In addition, you can always contact us by calling 1.877.977.9118 or, if your inquiry is not urgent, emailing us firstname.lastname@example.org.